Trials / Unknown
UnknownNCT02406716
Semaphorins 3A and 4D Levels in Heart Failure Patients
Semaphorins 3A and 4D Levels in Heart Failure Patients: Pathogenesis and Clinical Correlation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 120 (estimated)
- Sponsor
- Bnai Zion Medical Center · Other Government
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This study hypothesis is that Semaphorins 3A and 4D levels are overexpressed in patients with heart failure. Study protocol: Hospitallized patients with new onset or previously diagnosed heart failure will be recruited to the study. Control group will include healthy people with no medical records or chronic treatment at the same age range. After signing an informed constent form, full medical history and blood samples will be collected. A second blood sample will be collected 8 weeks later, assuming the patient was discharged and not hospitalized since than. The blood samples will be analyzed by Bnai Zion Medical Center Immunology labs for the above semaphorins levels in the heart failure group and control group. Statistical analysis will then commence for possible correlatoion with different clinical parameters.
Detailed description
In few previous published studies, Semaphorins 3A levels are overexpressed in patients with heart failure. The aim of our study is the compare semaphorin 3A and 4D in patients with acute decompansated heart failure with healthy donors. Second aim is to compare semaphorin level in the same patients in time of hospitalization and few weeks later when the heart failure presumingly controled. Statistical analysis will then commense for possible correlatoion with different clinical parameters like NYHA (new york heart association) status of the patient, lenghts of hospitalization and BNP (brain natriuretic peptide) levels at time of admition.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Biospecimen retention |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-05-01
- Completion
- 2017-05-01
- First posted
- 2015-04-02
- Last updated
- 2015-04-02
Source: ClinicalTrials.gov record NCT02406716. Inclusion in this directory is not an endorsement.